Impact of payment source, referral site, and place of residence on outcomes after allogeneic transplantation in Mexico

Table 2 Cox proportional hazards regression analysis of overall survival

		HR	95%CI	P value
Univariate analysis
Age	Continuous	1	0.99-1.01	0.77
Sex	Female	1	0.71-1.4	0.98
DRI	Benign	0.66	0.36-1.19	0.02
	Low	0.15	0.02-1.08
	Intermediate	0.66	0.46-0.94
Treatment lines	Continuous	1.13	0.99-1.28	0.06
HCT-CI	Continuous	1.1	0.87-1.3	0.56
Place of residence	Out of state	0.94	0.67-1.31	0.7
Reference	Non-local	0.99	0.71-1.38	0.95
Coverage	Universal	0.76	0.51-1.13	0.02
	Private	0.55	0.35-0.86
Donor	Haploidentical	1.48	1.03-2.1	0.03
Conditioning	NMA	0.94	0.53-1.67	0.92
	RIC	1.1	0.73-1.53
GVHD prophylaxis	PTCy	1.6	0.89-3.01	0.01
Multivariate analysis
DRI	Benign	0.64	0.3-1.37	0.25
	Low	0.15	0.02-1.12	0.06
	Intermediate	0.57	0.32-1	0.05
	High	0.9	0.52-1.58	0.72
Coverage	Federal	0.86	0.58-1.29	0.46
	Private	0.49	0.31-0.77	0.002
Donor	Haploidentical	0.93	0.56-1.53	0.78
GVDH prophylaxis	PTCy	1.64	0.89-3	0.11

DRI: Disease risk index; HCT-CI: Hematopoietic cell comorbidity index: GVHD: GRAFT versus host disease; NMA: Non-myeloablative; PTCy: Post-transplant cyclophosphamide.